These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic therapy for high-grade glioma. Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593 [TBL] [Abstract][Full Text] [Related]
6. Platinum-based chemotherapy in recurrent high-grade glioma patients: retrospective study. Roci E; Cakani B; Brace G; Bushati T; Rroji A; Petrela M; Kaloshi G Med Arch; 2014; 68(2):140-3. PubMed ID: 24937942 [TBL] [Abstract][Full Text] [Related]
7. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma. Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109 [TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND; Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525 [TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Ji N; Weng D; Liu C; Gu Z; Chen S; Guo Y; Fan Z; Wang X; Chen J; Zhao Y; Zhou J; Wang J; Ma D; Li N Oncotarget; 2016 Jan; 7(4):4369-78. PubMed ID: 26716896 [TBL] [Abstract][Full Text] [Related]
10. An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma. Goh J; De Mel S; Hoppe MM; Mohd Abdul Rashid MB; Zhang XY; Jaynes P; Ka Yan Ng E; Rahmat NDB; Jayalakshmi ; Liu CX; Poon L; Chan E; Lee J; Chee YL; Koh LP; Tan LK; Soh TG; Yuen YC; Loi HY; Ng SB; Goh X; Eu D; Loh S; Ng S; Tan D; Cheah DMZ; Pang WL; Huang D; Ong SY; Nagarajan C; Chan JY; Ha JCH; Khoo LP; Somasundaram N; Tang T; Ong CK; Chng WJ; Lim ST; Chow EK; Jeyasekharan AD Sci Transl Med; 2022 Oct; 14(667):eabn7824. PubMed ID: 36260690 [TBL] [Abstract][Full Text] [Related]
11. Temozolomide for high grade glioma. Hart MG; Garside R; Rogers G; Stein K; Grant R Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD007415. PubMed ID: 23633341 [TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. Hall PE; Lewis R; Syed N; Shaffer R; Evanson J; Ellis S; Williams M; Feng X; Johnston A; Thomson JA; Harris FP; Jena R; Matys T; Jefferies S; Smith K; Wu BW; Bomalaski JS; Crook T; O'Neill K; Paraskevopoulos D; Khadeir RS; Sheaff M; Pacey S; Plowman PN; Szlosarek PW Clin Cancer Res; 2019 May; 25(9):2708-2716. PubMed ID: 30796035 [TBL] [Abstract][Full Text] [Related]
13. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064 [TBL] [Abstract][Full Text] [Related]
15. Retrospective study of nivolumab for patients with recurrent high grade gliomas. Mantica M; Pritchard A; Lieberman F; Drappatz J J Neurooncol; 2018 Sep; 139(3):625-631. PubMed ID: 29779086 [TBL] [Abstract][Full Text] [Related]
16. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159 [TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic therapy for high-grade glioma. Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542 [TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
19. FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Colavolpe C; Chinot O; Metellus P; Mancini J; Barrie M; Bequet-Boucard C; Tabouret E; Mundler O; Figarella-Branger D; Guedj E Neuro Oncol; 2012 May; 14(5):649-57. PubMed ID: 22379188 [TBL] [Abstract][Full Text] [Related]
20. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. Blumenthal DT; Kanner AA; Aizenstein O; Cagnano E; Greenberg A; Hershkovitz D; Ram Z; Bokstein F World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]